#ES­MO20: Alk­er­mes of­fers their first snap­shot of a ben­e­fit for their next-gen IL-2 drug. But why did 1 pa­tient starve to death?

Every­one in the can­cer R&D are­na is look­ing to build new fran­chis­es around bet­ter drugs and com­bos. And one busy pock­et of that space is cen­tered en­tire­ly on cre­at­ing an IL-2 drug that can be as ef­fec­tive as the orig­i­nal with­out the tox­i­c­i­ty that damned it to the side­lines.

Alk­er­mes $ALKS for­mal­ly tossed its hat in­to the ring of con­tenders at vir­tu­al ES­MO to­day, high­light­ing the first glimpse of ef­fi­ca­cy for their can­di­date, ALKS 4230, as both a monother­a­py as well as in com­bi­na­tion with Mer­ck’s Keytru­da.

To read Endpoints News become a free subscriber

Unlock this article instantly, along with access to limited free monthly articles and our suite of newsletters

SIGN UP LOG IN